Masha Maharaj
Research Subjects
Masha Maharaj has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Nisaar Korowlay
Division of Nuclear Medicine, Stellenbosch University, Parow, Cape Town 7505, Western Cape, South Africa
3 shared publications - Trisha Govender
Department of Nuclear Medicine, Umhlanga Molecular Imaging & Therapy Centre of Excellence, Netcare Umhlanga Hospital, Umhlanga 4319, KwaZulu-Natal, South Africa
3 shared publications - Mike Sathekge
Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria, South Africa
2 shared publications Nisaar Korowlay
Division of Nuclear Medicine, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa
2 shared publications- Adrian C. Herington
Queensland University of Technology
1 shared publication - Aviral Singh
Theranostics Center for Molecular Radiotherapy and Molecular Imaging (PET/CT) ENETS Center of Excellence, Zentralklinik Bad Berka GmbH, Bad Berka, Germany
1 shared publication
Latest Publications
- Open Access
- 13 June 2026
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 41, 327-339
The State of Theragnostics in BRICS Nations: A Data-Driven Multicentre Report
Objectives: Theragnostic integrates diagnostic imaging with targeted radionuclide therapy, offering a precision approach in oncology. The BRICS Multicentre Theragnostic Survey (2025–2026) aimed to evaluate current clinical practices in radionuclide therapy across participating centres within BRICS member and partner countries. The survey aimed to assess clinical activity, patterns of therapeutic radionuclide utilisation, implementation of patient-specific dosimetry, and to identify key logistical, regulatory, infrastructural, and workforce-related challenges. It also sought to define institutional training needs and opportunities for collaborative development in theragnostic applications across the BRICS network. Material and Methods: A multicentre, cross-sectional survey was conducted using a structured questionnaire distributed to nuclear medicine and theragnostic centres across BRICS countries and affiliated partner nations. Aggregated, non-identifiable institutional-level data were collected on clinical workload, radiopharmaceutical targets, therapeutic radionuclides used, clinical indications, dosimetry practices (including SPECT, SPECT/CT, and PET/CT), operational challenges, proposed solutions, and training needs. Data were analysed descriptively. Results: A total of 137 centres from 14 countries participated in the BRICS Multicentre Theragnostic Survey 2026, with the largest contributions from India (n=72, 52.6%) and Indonesia (n=21, 15.3%), followed by South Africa (n=11, 8.0%), Brazil (n=10, 7.3%), China (n=5, 3.6%), Iran (n=4, 2.9%), and Republic of Belarus (n=4, 2.9%). The majority of institutions were private hospitals or clinics (51.1%), followed by academic/university hospitals (26.3%) and government/public hospitals (19.0%). Dedicated theragnostic services were established in 71.3% of centres. Procedure volumes varied widely, with 34.3% of centres performing fewer than 50 procedures per year and only 13.1% exceeding 500 annually. Prostate-specific membrane antigen (PSMA) based theragnostics were offered by 82.3%, and DOTATATE-based therapies by 70.8% of centres. 131 I was the most widely used therapeutic radionuclide (86.1%), followed by 177 Lu (73.7%). The leading clinical indications were thyroid cancer (90.8%), prostate cancer (82.4%), neuroendocrine tumours (70.2%), and bone metastases (60.3%). Patient-specific dosimetry was performed routinely in 8.0% and selectively in 35.8% of centres, while 51.1% reported not performing it at all. SPECT/CT was the predominant imaging modality among those performing dosimetry. Key challenges included limited radionuclide availability (82.4%), reimbursement and funding issues (77.4%), lack of harmonised regulations (72.5%), insufficient trained personnel (67.0%), import/export delays (56.3%), and licensing and authorisation delays (55.9%). Conclusion: This survey reveals substantial heterogeneity in theragnostic implementation across BRICS centres and highlights persistent gaps in radionuclide supply, reimbursement, regulatory harmonisation, infrastructure, and workforce capacity. Without coordinated intervention, current disparities in infrastructure, workforce, and radionuclide supply are likely to widen, limiting equitable access to theragnostic therapies across BRICS nations. Strengthening collaboration through the BRICS network offers a strategic pathway to expand equitable access to safe and effective theragnostic therapies across all disease stages.
- 13 June 2026
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 41, 327-339
Open AccessThe State of Theragnostics in BRICS Nations: A Data-Driven Multicentre Report
Objectives: Theragnostic integrates diagnostic imaging with targeted radionuclide therapy, offering a precision approach in oncology. The BRICS Multicentre Theragnostic Survey (2025–2026) aimed to evaluate current clinical practices in radionuclide therapy across participating centres within BRICS member and partner countries. The survey aimed to assess clinical activity, patterns of therapeutic radionuclide utilisation, implementation of patient-specific dosimetry, and to identify key logistical, regulatory, infrastructural, and workforce-related challenges. It also sought to define institutional training needs and opportunities for collaborative development in theragnostic applications across the BRICS network. Material and Methods: A multicentre, cross-sectional survey was conducted using a structured questionnaire distributed to nuclear medicine and theragnostic centres across BRICS countries and affiliated partner nations. Aggregated, non-identifiable institutional-level data were collected on clinical workload, radiopharmaceutical targets, therapeutic radionuclides used, clinical indications, dosimetry practices (including SPECT, SPECT/CT, and PET/CT), operational challenges, proposed solutions, and training needs. Data were analysed descriptively. Results: A total of 137 centres from 14 countries participated in the BRICS Multicentre Theragnostic Survey 2026, with the largest contributions from India (n=72, 52.6%) and Indonesia (n=21, 15.3%), followed by South Africa (n=11, 8.0%), Brazil (n=10, 7.3%), China (n=5, 3.6%), Iran (n=4, 2.9%), and Republic of Belarus (n=4, 2.9%). The majority of institutions were private hospitals or clinics (51.1%), followed by academic/university hospitals (26.3%) and government/public hospitals (19.0%). Dedicated theragnostic services were established in 71.3% of centres. Procedure volumes varied widely, with 34.3% of centres performing fewer than 50 procedures per year and only 13.1% exceeding 500 annually. Prostate-specific membrane antigen (PSMA) based theragnostics were offered by 82.3%, and DOTATATE-based therapies by 70.8% of centres. 131 I was the most widely used therapeutic radionuclide (86.1%), followed by 177 Lu (73.7%). The leading clinical indications were thyroid cancer (90.8%), prostate cancer (82.4%), neuroendocrine tumours (70.2%), and bone metastases (60.3%). Patient-specific dosimetry was performed routinely in 8.0% and selectively in 35.8% of centres, while 51.1% reported not performing it at all. SPECT/CT was the predominant imaging modality among those performing dosimetry. Key challenges included limited radionuclide availability (82.4%), reimbursement and funding issues (77.4%), lack of harmonised regulations (72.5%), insufficient trained personnel (67.0%), import/export delays (56.3%), and licensing and authorisation delays (55.9%). Conclusion: This survey reveals substantial heterogeneity in theragnostic implementation across BRICS centres and highlights persistent gaps in radionuclide supply, reimbursement, regulatory harmonisation, infrastructure, and workforce capacity. Without coordinated intervention, current disparities in infrastructure, workforce, and radionuclide supply are likely to widen, limiting equitable access to theragnostic therapies across BRICS nations. Strengthening collaboration through the BRICS network offers a strategic pathway to expand equitable access to safe and effective theragnostic therapies across all disease stages.
- Open Access
- 29 May 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (11) , 1684
Extraosseous 99mTc-MDP Uptake Guiding Intraoperative Sampling in Severe Inflammatory Myopathy: A Case Report and Literature Review
Background/Objectives: We report a case of severe dermatomyositis demonstrating characteristic widespread extraosseous uptake on 99mTc-methylene diphosphonate (99mTc-MDP) bone scintigraphy. This study highlights the diagnostic value of this modality in detecting active inflammatory myopathy when conventional muscle biopsy is inconclusive and introduces its novel use for intraoperative gamma-probe-guided biopsy to precisely target metabolically active muscle. This approach may help target metabolically active muscle in heterogeneous idiopathic inflammatory myopathies (IIMs). Case Presentation: A 49-year-old man developed progressive proximal muscle weakness (Medical Research Council grade 2/5 proximally, 5/5 distally) beginning in June 2025 following influenza infection, accompanied by dysphagia, classic dermatomyositis cutaneous manifestations, back pain, and difficulty standing. Laboratory evaluation revealed elevated inflammatory markers (ESR 55 mm/hr, CRP 20 mg/L), leukocytosis (16.58 × 109/L), markedly raised creatine kinase (19,937 IU/L), and troponin T levels. An initial quadriceps muscle biopsy performed on 29 July 2025 was non-diagnostic. Three-phase 99mTc-MDP scintigraphy (~1110 MBq) demonstrated intense, diffuse extraosseous uptake involving bilateral deltoids (symmetric), biceps and triceps (patchy), paraspinal muscles (longitudinal), gluteal muscles, thighs (quadriceps and hamstrings), and gastrocnemius muscles, with relative suppression of appendicular skeletal uptake on delayed images due to soft-tissue tracer dominance—findings consistent with severe inflammatory myopathy. Following reinjection (~1100 MBq), intraoperative gamma-probe-guided biopsy targeted areas of highest uptake (left quadriceps femoris and distal triceps brachii; intraoperative counts 1300–1400 versus background ~500). Histopathology revealed histiocyte-predominant inflammation with myofibre necrosis and regeneration, sparse CD4+ T-cell infiltrates, and absence of fibrosis, consistent with necrotising myopathy. Positive antinuclear antibodies and strong anti-Mi-2 antibodies confirmed the diagnosis of dermatomyositis. Treatment included pulse methylprednisolone followed by oral prednisone taper, methotrexate, azathioprine, intravenous immunoglobulin, and planned rituximab therapy. Discussion: Whole-body 99mTc-MDP scintigraphy provided a complementary whole-body functional assessment of disease extent, revealing widespread muscular involvement. The novel application of intraoperative gamma-probe-guided biopsy enabled real-time targeting of metabolically active muscle, facilitating targeted sampling after an initial non-diagnostic biopsy and yielding supportive histopathological findings. This dual diagnostic and interventional role demonstrates the technical feasibility of gamma-probe guidance in a diagnostically challenging case of dermatomyositis. Conclusions: In our case, the integration of 99mTc-MDP scintigraphy with gamma-probe-guided biopsy enabled precise targeting of metabolically active muscle following an initial non-diagnostic biopsy. This multimodal approach may be useful in selected diagnostically challenging cases of severe inflammatory myopathy. Larger studies are needed to evaluate its reproducibility and added value.
- 29 May 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (11) , 1684
Open AccessExtraosseous 99mTc-MDP Uptake Guiding Intraoperative Sampling in Severe Inflammatory Myopathy: A Case Report and Literature Review
Background/Objectives: We report a case of severe dermatomyositis demonstrating characteristic widespread extraosseous uptake on 99mTc-methylene diphosphonate (99mTc-MDP) bone scintigraphy. This study highlights the diagnostic value of this modality in detecting active inflammatory myopathy when conventional muscle biopsy is inconclusive and introduces its novel use for intraoperative gamma-probe-guided biopsy to precisely target metabolically active muscle. This approach may help target metabolically active muscle in heterogeneous idiopathic inflammatory myopathies (IIMs). Case Presentation: A 49-year-old man developed progressive proximal muscle weakness (Medical Research Council grade 2/5 proximally, 5/5 distally) beginning in June 2025 following influenza infection, accompanied by dysphagia, classic dermatomyositis cutaneous manifestations, back pain, and difficulty standing. Laboratory evaluation revealed elevated inflammatory markers (ESR 55 mm/hr, CRP 20 mg/L), leukocytosis (16.58 × 109/L), markedly raised creatine kinase (19,937 IU/L), and troponin T levels. An initial quadriceps muscle biopsy performed on 29 July 2025 was non-diagnostic. Three-phase 99mTc-MDP scintigraphy (~1110 MBq) demonstrated intense, diffuse extraosseous uptake involving bilateral deltoids (symmetric), biceps and triceps (patchy), paraspinal muscles (longitudinal), gluteal muscles, thighs (quadriceps and hamstrings), and gastrocnemius muscles, with relative suppression of appendicular skeletal uptake on delayed images due to soft-tissue tracer dominance—findings consistent with severe inflammatory myopathy. Following reinjection (~1100 MBq), intraoperative gamma-probe-guided biopsy targeted areas of highest uptake (left quadriceps femoris and distal triceps brachii; intraoperative counts 1300–1400 versus background ~500). Histopathology revealed histiocyte-predominant inflammation with myofibre necrosis and regeneration, sparse CD4+ T-cell infiltrates, and absence of fibrosis, consistent with necrotising myopathy. Positive antinuclear antibodies and strong anti-Mi-2 antibodies confirmed the diagnosis of dermatomyositis. Treatment included pulse methylprednisolone followed by oral prednisone taper, methotrexate, azathioprine, intravenous immunoglobulin, and planned rituximab therapy. Discussion: Whole-body 99mTc-MDP scintigraphy provided a complementary whole-body functional assessment of disease extent, revealing widespread muscular involvement. The novel application of intraoperative gamma-probe-guided biopsy enabled real-time targeting of metabolically active muscle, facilitating targeted sampling after an initial non-diagnostic biopsy and yielding supportive histopathological findings. This dual diagnostic and interventional role demonstrates the technical feasibility of gamma-probe guidance in a diagnostically challenging case of dermatomyositis. Conclusions: In our case, the integration of 99mTc-MDP scintigraphy with gamma-probe-guided biopsy enabled precise targeting of metabolically active muscle following an initial non-diagnostic biopsy. This multimodal approach may be useful in selected diagnostically challenging cases of severe inflammatory myopathy. Larger studies are needed to evaluate its reproducibility and added value.
- Open Access
Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders
Background: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PRLT) with Lutetium-177 ([177Lu]Lu-PSMA) is a safe and effective treatment for metastatic castration-resistant prostate cancer (mCRPC). The aim of our study was to evaluate clinical variables of patients with extreme response to PRLT and to assess its immunomodulatory potential. Methods: This retrospective study included 36 patients from two centers achieving extreme response after [¹⁷⁷Lu]Lu-PSMA PRLT. The primary outcomes were the duration of maintained response in months (MR) and improvement post-therapy—clinically, serologically, and on molecular (PET/CT) imaging. We examined several variables, including pathology, gene sequencing, baseline PSA, Gleason score, prior therapies, number of PRLT cycles, and pattern of disease, to identify potential factors that may influence the extreme response. Results: Between 2018 and mid-September 2024, 36 men with mCRPC received a mean of three cycles of [177Lu]Lu-PSMA PRLT. Patients were subgrouped according to clinical variables versus MR. A total of 17 patients had ≥12 months MR (17/36, 47%). The longest duration of MR was 99 months and a mean of 17.44 months (95% CI 10.05–24.84). Previous lines of treatment were evaluated for MR, p = 0.172. Pattern of disease (bone, lymph node, liver, and peritoneal) was evaluated for MR, p = 0.721. The Gleason score was evaluated for MR, p = 0.871. Patients with known BRCA sequencing status (n = 12) were analyzed with mean MR: BRCA1/2 wild-type, 6/12 (50%), 6.67 months; BRCA 1/2 negative, 1/12 (8.33%), 7 months; BRCA germline negative and somatic positive, 1/12 (8.33%), 36 months; BRCA germline negative, somatic negative, 2/12 (16.67%), 27 months; and BRCA 2 positive, 2/12 (16.67%), 43 months. Conclusions: We propose there may be intrinsic mechanisms suggesting the immunomodulatory enhancement of ionizing radiation, primarily driving extreme responses.
Open AccessIs Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders
Background: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PRLT) with Lutetium-177 ([177Lu]Lu-PSMA) is a safe and effective treatment for metastatic castration-resistant prostate cancer (mCRPC). The aim of our study was to evaluate clinical variables of patients with extreme response to PRLT and to assess its immunomodulatory potential. Methods: This retrospective study included 36 patients from two centers achieving extreme response after [¹⁷⁷Lu]Lu-PSMA PRLT. The primary outcomes were the duration of maintained response in months (MR) and improvement post-therapy—clinically, serologically, and on molecular (PET/CT) imaging. We examined several variables, including pathology, gene sequencing, baseline PSA, Gleason score, prior therapies, number of PRLT cycles, and pattern of disease, to identify potential factors that may influence the extreme response. Results: Between 2018 and mid-September 2024, 36 men with mCRPC received a mean of three cycles of [177Lu]Lu-PSMA PRLT. Patients were subgrouped according to clinical variables versus MR. A total of 17 patients had ≥12 months MR (17/36, 47%). The longest duration of MR was 99 months and a mean of 17.44 months (95% CI 10.05–24.84). Previous lines of treatment were evaluated for MR, p = 0.172. Pattern of disease (bone, lymph node, liver, and peritoneal) was evaluated for MR, p = 0.721. The Gleason score was evaluated for MR, p = 0.871. Patients with known BRCA sequencing status (n = 12) were analyzed with mean MR: BRCA1/2 wild-type, 6/12 (50%), 6.67 months; BRCA 1/2 negative, 1/12 (8.33%), 7 months; BRCA germline negative and somatic positive, 1/12 (8.33%), 36 months; BRCA germline negative, somatic negative, 2/12 (16.67%), 27 months; and BRCA 2 positive, 2/12 (16.67%), 43 months. Conclusions: We propose there may be intrinsic mechanisms suggesting the immunomodulatory enhancement of ionizing radiation, primarily driving extreme responses.
- Open Access
- 22 May 2023
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 22 (02) , 152-170
Hepatobiliary Study Showing Bile Reflux into the Gastric Mucosa
Drmasha@yahoo.co.uk Introduction: Hepatobiliary (HIDA) scintigraphy is a radionuclide diagnostic imaging study that tracks the production and flow of bile from the formative phase in the liver and its passage through the biliary system into the small intestine. It is performed to assess hepatocellular function and the biliary system. The clinical indication of this study includes acute cholecystitis, bile leakage, calculation of gallbladder ejection fraction (GBEF), functional assessment of the liver before partial hepatectomy, sphincter of Oddi dysfunction, among others. Aims and Objective: importance of Incidental finding of gastric bile reflux during hepatobiliary scan in patients presenting with symptoms for biliary dyskinesia. Methods: Three (3) patients in total were used in this study. The most common symptoms were nausea, diarrhea, and epigastric pain. The standard protocol was used with the patients fasting for 4 hours prior to scanning. Dynamic images were acquired for an hour post radiotracer administration with a dose of 370 MBq (99mTc bromo biliaron), followed by a reference static image of the same field of view. The patients were then instructed to eat a fatty meal to enhance gall bladder contraction. A static image of the abdomen was acquired an hour after the previous reference static image in order for us to create time activity curves. The acquired images were then processed using the Xeleris program. Results: The findings showed good hepatocyte function in 100% of the patients; however, 66.7% showed bile gastric reflux. 33.3% of the patients showed no bile gastric reflux. Conclusion: This study showed incidental findings of gastric bile reflux during a hepatobiliary scintigraphy which is commonly performed to assess hepatocyte and gallbladder function. These finding change the patient management and resulted in good clinical outcomes. Article published online: 25 May 2023 © 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 22 May 2023
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 22 (02) , 152-170
Open AccessHepatobiliary Study Showing Bile Reflux into the Gastric Mucosa
Drmasha@yahoo.co.uk Introduction: Hepatobiliary (HIDA) scintigraphy is a radionuclide diagnostic imaging study that tracks the production and flow of bile from the formative phase in the liver and its passage through the biliary system into the small intestine. It is performed to assess hepatocellular function and the biliary system. The clinical indication of this study includes acute cholecystitis, bile leakage, calculation of gallbladder ejection fraction (GBEF), functional assessment of the liver before partial hepatectomy, sphincter of Oddi dysfunction, among others. Aims and Objective: importance of Incidental finding of gastric bile reflux during hepatobiliary scan in patients presenting with symptoms for biliary dyskinesia. Methods: Three (3) patients in total were used in this study. The most common symptoms were nausea, diarrhea, and epigastric pain. The standard protocol was used with the patients fasting for 4 hours prior to scanning. Dynamic images were acquired for an hour post radiotracer administration with a dose of 370 MBq (99mTc bromo biliaron), followed by a reference static image of the same field of view. The patients were then instructed to eat a fatty meal to enhance gall bladder contraction. A static image of the abdomen was acquired an hour after the previous reference static image in order for us to create time activity curves. The acquired images were then processed using the Xeleris program. Results: The findings showed good hepatocyte function in 100% of the patients; however, 66.7% showed bile gastric reflux. 33.3% of the patients showed no bile gastric reflux. Conclusion: This study showed incidental findings of gastric bile reflux during a hepatobiliary scintigraphy which is commonly performed to assess hepatocyte and gallbladder function. These finding change the patient management and resulted in good clinical outcomes. Article published online: 25 May 2023 © 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 26 October 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48 (2) , e69-e70
Exceptional Response of Rare Plasmacytoid Variant Prostate Cancer Post 177Lu-PSMA Therapy Seen on 68Ga-PSMA PET/CT
Plasmacytoid is a rare variant of acinar prostatic adenocarcinoma. The aggressive type is characterized by an aggressive clinical course, lack of responsiveness to hormonal therapies, and an overall poor prognosis. Here we present pretherapy and posttherapy 68Ga-PSMA PET/CT images showing an exceptional response to 177Lu-PSMA therapy. This case demonstrates the usefulness of both 68Ga-PSMA PET/CT in assessing the tumor PSMA avidity and the potential of 177Lu-PSMA therapy in these patients.
- 26 October 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48 (2) , e69-e70
Exceptional Response of Rare Plasmacytoid Variant Prostate Cancer Post 177Lu-PSMA Therapy Seen on 68Ga-PSMA PET/CT
Plasmacytoid is a rare variant of acinar prostatic adenocarcinoma. The aggressive type is characterized by an aggressive clinical course, lack of responsiveness to hormonal therapies, and an overall poor prognosis. Here we present pretherapy and posttherapy 68Ga-PSMA PET/CT images showing an exceptional response to 177Lu-PSMA therapy. This case demonstrates the usefulness of both 68Ga-PSMA PET/CT in assessing the tumor PSMA avidity and the potential of 177Lu-PSMA therapy in these patients.
- 13 April 2021
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 55 (3) , 136-140
The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report
Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PSMA-RLT) with lutetium-177 (177Lu-PSMA) has been used in metastatic castrate-resistant prostate cancer (mCRPC), and retrospective data have shown this therapy to be favourably safe with attractive clinical responses. Re-challenge 177Lu-PSMA therapy in early responders has been shown to be safe and effective. We report the use of low-dose Taxol-based chemotherapy (modified dose 25 mg/m2 weekly × 6 weeks) as a radiosensitizer with re-challenge 177Lu-PSMA therapy (4 cycles). In a period of 3 years, the patient underwent a total of 8 cycles of 177Lu-PSMA with a cumulative dose of 51.8 GBq. All therapies were uneventful and well tolerated. There was a good response to re-challenge 177Lu-PSMA therapy and low-dose docetaxel (Taxol-177Lu-PSMA) with no recorded tumour resistance.
- 13 April 2021
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 55 (3) , 136-140
The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report
Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PSMA-RLT) with lutetium-177 (177Lu-PSMA) has been used in metastatic castrate-resistant prostate cancer (mCRPC), and retrospective data have shown this therapy to be favourably safe with attractive clinical responses. Re-challenge 177Lu-PSMA therapy in early responders has been shown to be safe and effective. We report the use of low-dose Taxol-based chemotherapy (modified dose 25 mg/m2 weekly × 6 weeks) as a radiosensitizer with re-challenge 177Lu-PSMA therapy (4 cycles). In a period of 3 years, the patient underwent a total of 8 cycles of 177Lu-PSMA with a cumulative dose of 51.8 GBq. All therapies were uneventful and well tolerated. There was a good response to re-challenge 177Lu-PSMA therapy and low-dose docetaxel (Taxol-177Lu-PSMA) with no recorded tumour resistance.
- 8 April 2020
- Published by Georg Thieme Verlag KG
- Vol. 59 (02) , L14
The impact of prior therapies on overall survival in mCRPC patients receiving Lu-PSMA-617 therapy. A WARMTH retrospective multicenter trial
Ziel/Aim The impact of prior therapies, especially chemotherapy, on overall survival (OS) in patients with castration-resistant prostate cancer (CRPC) receiving Lu-PSMA-617 therapy has been the subject of controversy. Therefore, WARMTH performed a multicentre analysis of more than 300 patients to evaluate OS. The study’s primary aim was to determine the OS rate and evaluate the predictive factors of OS and the impact of prior therapieson it. Methodik/Methods The data of 631 mCRPC patients from 11 different clinics were evaluated. According to the inclusion and exclusion criteria, all patients had to have received at least abiraterone or enzalutamide prior to Lu-PSMA-617 therapy. The patients were divided into three groups: patients who had received prior chemotherapy, patients who avoided chemotherapy and patients for whom a chemotherapy was contraindicated Ergebnisse/Results The analysis included the data of 453 patients, with a median age of 71.3 years. At the time of analysis, 138 patients (30 %) were still alive. Fifty-four percent of patients had received both abiraterone and enzalutamide; 76.2 % and 27.2 % had a history of chemotherapy with docetaxel and cabazitaxel, respectively. Twenty-two percent had had Ra-223. Patients without any prior chemotherapy showed a significantly longer OS (14.3 months vs. 10.7 months; p:0.015). There was no difference in OS between patients who had not received chemotherapy and patients for whom chemotherapy was contraindicated. Apart from significantly shorter OS in patients who underwent therapy with enzalutamide concurrently with the PSMA therapy, the other prior therapies did not have any significant impact on OS. Schlussfolgerungen/Conclusions CRPC patients receiving Lu-PSMA-617 therapy, who had not received prior chemotherapy, had better OS than patients with a history of chemotherapy. Apart from ongoing therapy with enzalutamide, other prior chemotherapy had no impact on OS
- 8 April 2020
- Published by Georg Thieme Verlag KG
- Vol. 59 (02) , L14
The impact of prior therapies on overall survival in mCRPC patients receiving Lu-PSMA-617 therapy. A WARMTH retrospective multicenter trial
Ziel/Aim The impact of prior therapies, especially chemotherapy, on overall survival (OS) in patients with castration-resistant prostate cancer (CRPC) receiving Lu-PSMA-617 therapy has been the subject of controversy. Therefore, WARMTH performed a multicentre analysis of more than 300 patients to evaluate OS. The study’s primary aim was to determine the OS rate and evaluate the predictive factors of OS and the impact of prior therapieson it. Methodik/Methods The data of 631 mCRPC patients from 11 different clinics were evaluated. According to the inclusion and exclusion criteria, all patients had to have received at least abiraterone or enzalutamide prior to Lu-PSMA-617 therapy. The patients were divided into three groups: patients who had received prior chemotherapy, patients who avoided chemotherapy and patients for whom a chemotherapy was contraindicated Ergebnisse/Results The analysis included the data of 453 patients, with a median age of 71.3 years. At the time of analysis, 138 patients (30 %) were still alive. Fifty-four percent of patients had received both abiraterone and enzalutamide; 76.2 % and 27.2 % had a history of chemotherapy with docetaxel and cabazitaxel, respectively. Twenty-two percent had had Ra-223. Patients without any prior chemotherapy showed a significantly longer OS (14.3 months vs. 10.7 months; p:0.015). There was no difference in OS between patients who had not received chemotherapy and patients for whom chemotherapy was contraindicated. Apart from significantly shorter OS in patients who underwent therapy with enzalutamide concurrently with the PSMA therapy, the other prior therapies did not have any significant impact on OS. Schlussfolgerungen/Conclusions CRPC patients receiving Lu-PSMA-617 therapy, who had not received prior chemotherapy, had better OS than patients with a history of chemotherapy. Apart from ongoing therapy with enzalutamide, other prior chemotherapy had no impact on OS
- Open Access
- 1 July 2018
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 17 (03) , 178-181
The association of human immunodeficiency virus and skeletal metastases in breast cancer using Tc-99m methyl diphosphonate bone scan
Skeletal involvement occurs in 30%–70% of all cancer patients, with breast cancer (BC) being the leading cause for bone metastases in women and prostate cancer in men followed by lung cancer. Human immunodeficiency virus (HIV) is a lentivirus (a member of the retrovirus family) that causes acquired immunodeficiency syndrome. It is yet unknown what is the impact of HIV to the onset and progression of bone disease in BC. The purpose of the study was to determine the association of HIV infection and skeletal metastases in BC using skeletal scintigraphy. A retrospective analysis of 25 female BC patients' bone scans was performed. The 25 bone scans of 12 patients known HIV positive and 13 patients who were known HIV negative, of similar age and histology, were compared. All 13 HIV negative patients had a positive bone scan. Of the 12 HIV-positive patients, 4 patients on highly active antiretroviral therapy (HAART) had positive bone scans for skeletal metastases. The remaining eight HIV-positive patients had negative bone scans, of which six were on HAART and two were not on HAART. In our study, HIV infection was not found to be a contributing risk factor for skeletal metastases. From our small series, it appears that HIV patients and on HAART have a delay in the onset of skeletal metastases in BC.
- 1 July 2018
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 17 (03) , 178-181
Open AccessThe association of human immunodeficiency virus and skeletal metastases in breast cancer using Tc-99m methyl diphosphonate bone scan
Skeletal involvement occurs in 30%–70% of all cancer patients, with breast cancer (BC) being the leading cause for bone metastases in women and prostate cancer in men followed by lung cancer. Human immunodeficiency virus (HIV) is a lentivirus (a member of the retrovirus family) that causes acquired immunodeficiency syndrome. It is yet unknown what is the impact of HIV to the onset and progression of bone disease in BC. The purpose of the study was to determine the association of HIV infection and skeletal metastases in BC using skeletal scintigraphy. A retrospective analysis of 25 female BC patients' bone scans was performed. The 25 bone scans of 12 patients known HIV positive and 13 patients who were known HIV negative, of similar age and histology, were compared. All 13 HIV negative patients had a positive bone scan. Of the 12 HIV-positive patients, 4 patients on highly active antiretroviral therapy (HAART) had positive bone scans for skeletal metastases. The remaining eight HIV-positive patients had negative bone scans, of which six were on HAART and two were not on HAART. In our study, HIV infection was not found to be a contributing risk factor for skeletal metastases. From our small series, it appears that HIV patients and on HAART have a delay in the onset of skeletal metastases in BC.
- Open Access
- 1 January 2016
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 15 (01) , 50-52
The complimentary role of Methoxy-Isobutyl-Isonitrile and hand-held gamma probe in adamantinoma
Adamantinoma is a rare locally aggressive osteolytic tumor that is found 90% of the time in the diaphysis of the tibia with the remaining lesions found in the fibula and long tubular bones. A case of adamantinoma of the tibia is presented. The added value of nuclear medicine investigations in the workup of this patient is described. A three-phase whole body 99mTc-methylene diphosphonate bone and a whole body 99mTc-methoxy-isobutyl-isonitrile scans were complimentary in the demarcation of viable bone tumor and the assessment of the remainder of the bone and soft tissue to exclude other sites. Intra-operative assistance with a hand-held gamma probe, guided the biopsy of the most metabolically active tumor tissue. Histology revealed a biphasic tumor composed of epithelial and fibrous components, in keeping with an adamantinoma.
- 1 January 2016
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 15 (01) , 50-52
Open AccessThe complimentary role of Methoxy-Isobutyl-Isonitrile and hand-held gamma probe in adamantinoma
Adamantinoma is a rare locally aggressive osteolytic tumor that is found 90% of the time in the diaphysis of the tibia with the remaining lesions found in the fibula and long tubular bones. A case of adamantinoma of the tibia is presented. The added value of nuclear medicine investigations in the workup of this patient is described. A three-phase whole body 99mTc-methylene diphosphonate bone and a whole body 99mTc-methoxy-isobutyl-isonitrile scans were complimentary in the demarcation of viable bone tumor and the assessment of the remainder of the bone and soft tissue to exclude other sites. Intra-operative assistance with a hand-held gamma probe, guided the biopsy of the most metabolically active tumor tissue. Histology revealed a biphasic tumor composed of epithelial and fibrous components, in keeping with an adamantinoma.
- 17 November 2014
- Published by Taylor & Francis in Growth Factors
- Vol. 32 (6) , 207-213
Inhibiting Eph kinase activity may not be “Eph”ective for cancer treatment
Several Eph receptor tyrosine kinases (RTKs) are commonly over-expressed in epithelial and mesenchymal cancers and are recognized as promising therapeutic targets. Although normal interaction between Eph receptors and their ephrin ligands stimulates kinase activity and is generally tumor suppressive, significant Eph over-expression allows activation of ligand- and/or kinase-independent signaling pathways that promote oncogenesis. Single-agent kinase inhibitors are widely used to target RTK-driven tumors but acquired and de novo resistance to such agents is a major limitation to effective clinical use. Accumulating evidence suggests that Ephs can be inhibited by “leaky” or low-specificity kinase inhibitors targeted at other RTKs. Such off-target effects may therefore inadvertently promote ligand- and/or kinase-independent oncogenic Eph signaling, thereby providing a new mechanism by which resistance to the RTK inhibitors can emerge. We propose that combining specific, non-leaky kinase inhibitors with tumor-suppressive stimulators of Eph signaling may provide more effective treatment options for overcoming treatment-induced resistance and clinical failure.
- 17 November 2014
- Published by Taylor & Francis in Growth Factors
- Vol. 32 (6) , 207-213
Inhibiting Eph kinase activity may not be “Eph”ective for cancer treatment
Several Eph receptor tyrosine kinases (RTKs) are commonly over-expressed in epithelial and mesenchymal cancers and are recognized as promising therapeutic targets. Although normal interaction between Eph receptors and their ephrin ligands stimulates kinase activity and is generally tumor suppressive, significant Eph over-expression allows activation of ligand- and/or kinase-independent signaling pathways that promote oncogenesis. Single-agent kinase inhibitors are widely used to target RTK-driven tumors but acquired and de novo resistance to such agents is a major limitation to effective clinical use. Accumulating evidence suggests that Ephs can be inhibited by “leaky” or low-specificity kinase inhibitors targeted at other RTKs. Such off-target effects may therefore inadvertently promote ligand- and/or kinase-independent oncogenic Eph signaling, thereby providing a new mechanism by which resistance to the RTK inhibitors can emerge. We propose that combining specific, non-leaky kinase inhibitors with tumor-suppressive stimulators of Eph signaling may provide more effective treatment options for overcoming treatment-induced resistance and clinical failure.